Zafgen to Present at the 2017 Ladenburg Thalmann Healthcare Conference
20 September 2017 - 6:05AM
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated
to significantly improving the health and well-being of patients
affected by metabolic diseases including type 2 diabetes and
obesity, announced today that Thomas Hughes, Ph.D., President and
Chief Executive Officer of Zafgen, will present at the 2017
Ladenburg Thalmann Healthcare Conference in New York City on
Tuesday, September 26, 2017 at 1:00 p.m. ET.
A live audio webcast and replay of the
presentation will be available through the Events and Presentations
page of the Investors section of the Company's website
(www.zafgen.com) for 90 days following the conclusion of the live
event.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical
company dedicated to significantly improving the health and
well-being of patients affected by metabolic diseases including
type 2 diabetes and obesity. Zafgen is focused on developing novel
therapeutics that treat the underlying biological mechanisms of
metabolic diseases through the MetAP2 pathway. The Company has
pioneered the study of MetAP2 inhibitors in both common and rare
forms of obesity, and in patients affected by type 2 diabetes.
Zafgen’s lead product candidate is ZGN-1061, a fumagillin-class,
injectable small molecule second generation MetAP2 inhibitor that
was advanced into development due to its unique properties that
maximize impact on metabolic parameters relevant to the treatment
of type 2 diabetes and other related metabolic disorders. The
Company recently completed its first Phase 1 clinical trial of
ZGN-1061, and is in Phase 2 clinical testing in patients with type
2 diabetes who are overweight or obese. Zafgen holds exclusive
worldwide rights for the development and commercialization of
ZGN-1061. Zafgen aspires to improve the lives of patients through
targeted treatments and has assembled a team accomplished in
bringing therapies to patients affected by metabolic diseases.
Media/Investor Relations Contact:
Zafgen, Inc.Patricia AllenChief Financial
Officer617-648-9792
Argot PartnersInvestor RelationsLaura Perry
212-600-1902laura@argotpartners.com
Spectrum ScienceMedia RelationsMichelle
Strier202-587-2582mstrier@spectrumscience.com
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Apr 2024 to May 2024
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Zafgen Inc (NASDAQ): 0 recent articles
More News Articles